Wegovy vs Zepbound: Which One Actually Works Better?

The core difference is how many hormones each drug activates. Wegovy contains semaglutide, which mimics one gut hormone called GLP-1 (glucagon-like peptide-1) — a hormone that slows digestion, curbs appetite, and quiets food noise (persistent intrusive thoughts about eating). Zepbound contains tirzepatide, a *dual agonist* that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), a second hormone that appears to improve how your body handles fat and sugar. Both are once-weekly injections approved specifically for chronic weight management, and both come from the same medication families used for type 2 diabetes (Ozempic and Mounjaro). Because Zepbound hits two targets instead of one, researchers expected it to produce more weight loss — and the head-to-head data confirmed that. If you want a deeper look at the diabetes-branded versions, see our guide on [Mounjaro vs Zepbound](/blog/mounjaro-vs-zepbound-same-drug-different-goal) and [Ozempic vs Wegovy](/blog/ozempic-vs-wegovy-same-drug-key-differences).

Zepbound produced significantly more weight loss than Wegovy in the only direct head-to-head trial. In SURMOUNT-5 (NEJM 2025), a 72-week study of 751 adults with obesity, participants on tirzepatide (Zepbound) lost 20.2% of their body weight on average, while those on semaglutide (Wegovy) lost 13.7% — a roughly 47% greater relative weight loss. In pounds, that was about 50 lb (22.8 kg) versus 33 lb (15.0 kg). Zepbound users also lost more inches around the waist (-18.4 cm vs -13.0 cm), and 44% of them hit at least 15% weight loss by week 24 compared with 21% on Wegovy. This matches the broader trial programs: Wegovy's STEP 1 trial showed about 14.9% average loss, while Zepbound's SURMOUNT-1 trial showed up to 20.9% at the highest dose. The pattern is consistent — on average, Zepbound delivers more weight loss. That said, "average" hides big individual variation, and many people reach their goals on either drug.

Yes — Wegovy's biggest advantage is its proven heart-protection data. Wegovy is FDA-approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults with heart disease and obesity, based on the landmark SELECT trial (NEJM 2023), which followed more than 17,000 people and found a 20% reduction in major cardiovascular events. Zepbound does not yet carry that specific approval, though its own cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing. Wegovy has also been on the market longer with a larger real-world safety track record, and its lower-dose titration can feel gentler for some people starting out. For anyone whose primary concern is protecting their heart — not just the number on the scale — Wegovy's evidence base is a meaningful point in its favor. You can read more in our deep dive on [GLP-1 and heart health from the SELECT trial](/blog/glp1-heart-health-select-trial-cardiovascular-benefits).

Side effects are broadly similar because both work by slowing digestion. The most common issues for both drugs are nausea, constipation, diarrhea, vomiting, and bloating — usually worst in the first weeks and after each dose increase. In SURMOUNT-5, the overall rates of gastrointestinal side effects were comparable between the two, and serious side effects were uncommon in both groups. Some people find one drug easier on their stomach than the other, which is highly individual. Both carry the same boxed warning about a rare risk of thyroid C-cell tumors seen in rodent studies, so neither is recommended if you have a personal or family history of medullary thyroid cancer or MEN2 (multiple endocrine neoplasia type 2). Practical management — eating slowly, prioritizing protein, staying hydrated, and increasing the dose gradually — works for both. For hands-on relief, see our guides on [GLP-1 constipation](/blog/glp1-constipation-why-it-happens-and-how-to-fix-it) and [GLP-1 bloating](/blog/glp1-bloating-why-you-feel-puffy-how-to-fix-it).

Cost and access often decide the choice more than the efficacy gap. Both drugs have a list price of roughly $1,000-$1,350 per month without insurance, though manufacturer savings programs and cash-pay self-injection options through the makers' direct pharmacies have lowered real-world prices for many people. Insurance coverage for weight loss remains inconsistent — many plans cover one drug and not the other, or require you to try a cheaper option first. Because the two come from different manufacturers, your formulary may strongly favor one. Before assuming you can't afford either, check savings cards, telehealth providers, and pre-tax accounts. Our guides on [how to get GLP-1 medications cheaper](/blog/how-to-get-glp1-cheaper-savings-cards-telehealth-2026) and [whether insurance covers GLP-1 for weight loss](/blog/does-insurance-cover-glp1-for-weight-loss-2026) walk through the current options step by step. The bottom line: the "better" drug on paper isn't better if you can't sustainably access it.